sharetrader
Page 1136 of 1146 FirstFirst ... 136636103610861126113211331134113511361137113811391140 ... LastLast
Results 17,026 to 17,040 of 17185
  1. #17026
    Member
    Join Date
    Aug 2017
    Posts
    49

    Default

    Quote Originally Posted by blackcap View Post
    How does getting money for 17k tests make them cashflow positive? lets say $500 per test by my calcs that is $8,500,000. So would still be operating at a loss.
    The reimbursement rate was agreed last October at USD$760 per test

  2. #17027
    Member
    Join Date
    Aug 2017
    Posts
    49

    Default

    Quote Originally Posted by Balance View Post
    Check this out :

    Director, Market Access and Reimbursement
    Pacific Edge Diagnostics USA Ltd.
    Hershey, PA

    Responsible for the development and implementation of all market access strategies to secure and maintain access, coverage and reimbursement for all Pacific Edge Diagnostics products within the U.S.

    • Developed and implemented all payer coverage strategies for Medicare, and Commercial payers which resulted in positive reimbursement for CxBladder.
    • Collaborated with CMS to ensure appropriate implementation of access and pricing strategy regarding the new CMS proposed rule.
    • Developed and submitted Federal Supply Schedule packet to secure access to CxBladder in VA/DOD as well as appropriate government pricing.
    • Created and implemented field reimbursement strategies to support providers and internal stakeholders by removing reimbursement barriers and creating access to CxBladder.
    • Collaborated with a cross-functional team of marketing, sales and medical affairs leaders to develop and implement tools to support commercial payers, Medicare, Medicaid and CMS, reimbursement initiatives.
    • Effectively solicited, cultivated and established Key Opinion Leaders and CAC members, both regionally and nationally to support payer and reimbursement initiatives.
    • Responsible for the over sight and implementation of pricing and contracting strategy for all key customer segments which resulted in increase access and reimbursement for CxBladder
.
    • Developed clinical payer scientific dossier to support coverage of CxBladder.
    • Successfully developed and submitted to Medicare MAC the clinical value proposition, validation, and utility dossier for LCD reconsideration coverage inclusion of CxBladder.
    • Developed and Implemented the Pacific Edge Patient Financial Assistance Program to ensure financial access to Cxbladder



    He left the job 4 years ago

  3. #17028
    Legend
    Join Date
    Feb 2003
    Posts
    9,634

    Default

    Quote Originally Posted by Nigelk View Post
    He left the job 4 years ago
    Precisely!

    Note the "Successfully developed and submitted to Medicare MAC the clinical value proposition, validation, and utility dossier for LCD reconsideration coverage inclusion of CxBladder."

    Looks to me like PEB was rejected for LCD consideration 5 years ago! Was never mentioned once by DD or the company - it was all rah rah rah go go go, remember?
    Last edited by Balance; 21-06-2019 at 06:38 PM.

  4. #17029
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,383

    Default

    "Iterative" was the key word from past company advice.

  5. #17030
    Legend
    Join Date
    Feb 2003
    Posts
    9,634

    Default

    Quote Originally Posted by Minerbarejet View Post
    "Iterative" was the key word from past company advice.
    Yup - that's PEB, same repetitive story just as this NBR headline :

    https://www.nbr.co.nz/analysis/pacif...ss-or-oblivion

  6. #17031
    Junior Member
    Join Date
    Mar 2019
    Posts
    20

    Default

    Clinical study supports adoption of Cxbladder

    24/6/2019, 12:26 pmGENERALCLINICAL STUDY SUPPORTS ADOPTION OF CXBLADDER INTO NEW CLINCAL PATHWAY
    Canterbury DHB publishes real-world clinical study with cementing evidence supporting the adoption of Cxbladder into the new clinical pathway


    https://www.nzx.com/announcements/336487

  7. #17032
    Senior Member
    Join Date
    Jul 2015
    Location
    Napier
    Posts
    858

    Default

    Quote Originally Posted by Drew95 View Post
    Clinical study supports adoption of Cxbladder

    24/6/2019, 12:26 pmGENERALCLINICAL STUDY SUPPORTS ADOPTION OF CXBLADDER INTO NEW CLINCAL PATHWAY
    Canterbury DHB publishes real-world clinical study with cementing evidence supporting the adoption of Cxbladder into the new clinical pathway


    https://www.nzx.com/announcements/336487
    Great show me money and please don’t ask for anymore the dilution is killing shareholders wealth

  8. #17033
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,383

    Default

    Quote Originally Posted by Balance View Post
    Yup - that's PEB, same repetitive story just as this NBR headline :

    https://www.nbr.co.nz/analysis/pacif...ss-or-oblivion

    Why do you think they called it Pacific Edge?

  9. #17034
    Advanced Member
    Join Date
    Jul 2004
    Location
    Bolivia.
    Posts
    1,505

    Default

    If PEB were really that ****-hot, surely a big fish after all these years would have come down to NZ, paid say $150m for them ($112m market cap today), taken them out and then rammed through all the approvals and various hoops to jump through. Big companies have experts in those areas.

    While I don't necessarily doubt the science, surely it must start to get a little old and get superseded after this many years??

    2 ponderings on a Monday arvo…….

  10. #17035
    Legend
    Join Date
    Feb 2003
    Posts
    9,634

    Default

    Quote Originally Posted by Sideshow Bob View Post
    If PEB were really that ****-hot, surely a big fish after all these years would have come down to NZ, paid say $150m for them ($112m market cap today), taken them out and then rammed through all the approvals and various hoops to jump through. Big companies have experts in those areas.

    While I don't necessarily doubt the science, surely it must start to get a little old and get superseded after this many years??

    2 ponderings on a Monday arvo…….
    You obviously have not talked to DD.

    https://www.nbr.co.nz/article/pacifi...ng-cs-p-161995

    Any day now.

  11. #17036
    Advanced Member
    Join Date
    Jul 2004
    Location
    Bolivia.
    Posts
    1,505

    Default

    Quote Originally Posted by Balance View Post
    You obviously have not talked to DD.

    https://www.nbr.co.nz/article/pacifi...ng-cs-p-161995

    Any day now.
    What year was that from?? Or is that an annual plea to get taken over??

  12. #17037
    Legend
    Join Date
    Feb 2003
    Posts
    9,634

    Default

    Quote Originally Posted by Sideshow Bob View Post
    What year was that from?? Or is that an annual plea to get taken over??
    Haha - 4 years ago.
    Last edited by Balance; 25-06-2019 at 07:14 AM.

  13. #17038
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,383

    Default

    Quote Originally Posted by Sideshow Bob View Post
    If PEB were really that ****-hot, surely a big fish after all these years would have come down to NZ, paid say $150m for them ($112m market cap today), taken them out and then rammed through all the approvals and various hoops to jump through. Big companies have experts in those areas.

    While I don't necessarily doubt the science, surely it must start to get a little old and get superseded after this many years??

    2 ponderings on a Monday arvo…….
    Slowly, bit by bit, the various pieces of the puzzle are coming together.

    How many big fish do you see out there trying to and succeeding in changing CLINICAL PATHWAYS?
    Last edited by Minerbarejet; 24-06-2019 at 04:44 PM.

  14. #17039
    Member
    Join Date
    Jul 2015
    Posts
    355

    Default

    Quote Originally Posted by Minerbarejet View Post
    Slowly, bit by bit, the various pieces of the puzzle are coming together.

    How many big fish do you see out there trying to and succeeding in changing CLINICAL PATHWAYS?
    I'm sure they have popped up on the M&A radar for a number of the bigger players. Likely they did the assessment and judged it overvalued, the market too small or with too low a ROI. Maybe one of them is waiting for either a liquidation and buying the scraps (patents/IP) or for them to actually make it and then buy.

    And plenty are out there doing it... Few years ago BD wiped the slate clean of almost all chemical ID testing in microbiology (100+ years of use) with the introduction of the biotyper

  15. #17040
    Member
    Join Date
    Jul 2015
    Posts
    355

    Default

    And another point.... the NZ diagnostics community is very open to novel technologies, there are methodologies being run here which are years ahead of the USA due to the FDA licensing requirements. Makes it more surprising why they didnt pick up PEB earlier....

Tags for this Thread

Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •